123 related articles for article (PubMed ID: 16806963)
1. Cetuximab in advanced non-small cell lung cancer.
Rossi A; Maione P; Gridelli C
Crit Rev Oncol Hematol; 2006 Aug; 59(2):139-49. PubMed ID: 16806963
[TBL] [Abstract][Full Text] [Related]
2. The role of cetuximab and other epidermal growth factor receptor monoclonal antibodies in the treatment of advanced non-small cell lung cancer.
Rossi A; Bria E; Maione P; Palazzolo G; Falanga M; Gridelli C
Rev Recent Clin Trials; 2008 Sep; 3(3):217-27. PubMed ID: 18782080
[TBL] [Abstract][Full Text] [Related]
3. Cetuximab in advanced non-small cell lung cancer.
Govindan R
Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4241s-4244s. PubMed ID: 15217966
[TBL] [Abstract][Full Text] [Related]
4. Monoclonal antibodies against EGFR in non-small cell lung cancer.
Pirker R; Filipits M
Crit Rev Oncol Hematol; 2011 Oct; 80(1):1-9. PubMed ID: 21109448
[TBL] [Abstract][Full Text] [Related]
5. Cetuximab in non-small-cell lung cancer.
Carillio G; Montanino A; Costanzo R; Sandomenico C; Piccirillo MC; Di Maio M; Daniele G; Giordano P; Bryce J; Normanno N; Rocco G; Perrone F; Morabito A
Expert Rev Anticancer Ther; 2012 Feb; 12(2):163-75. PubMed ID: 22316364
[TBL] [Abstract][Full Text] [Related]
6. Is there a role for cetuximab in non small cell lung cancer?
Morgensztern D; Govindan R
Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4602-5. PubMed ID: 17671149
[TBL] [Abstract][Full Text] [Related]
7. Tumor growth inhibition with cetuximab and chemotherapy in non-small cell lung cancer xenografts expressing wild-type and mutated epidermal growth factor receptor.
Steiner P; Joynes C; Bassi R; Wang S; Tonra JR; Hadari YR; Hicklin DJ
Clin Cancer Res; 2007 Mar; 13(5):1540-51. PubMed ID: 17332300
[TBL] [Abstract][Full Text] [Related]
8. The evolving role of cetuximab in non-small cell lung cancer.
Lilenbaum RC
Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4432s-4435s. PubMed ID: 16857823
[TBL] [Abstract][Full Text] [Related]
9. The role of bevacizumab in the treatment of non-small cell lung cancer: current indications and future developments.
Gridelli C; Maione P; Rossi A; De Marinis F
Oncologist; 2007 Oct; 12(10):1183-93. PubMed ID: 17962612
[TBL] [Abstract][Full Text] [Related]
10. Clinical relevance of monoclonal antibodies in non small cell lung cancer.
Filipits M
J BUON; 2009 Sep; 14 Suppl 1():S147-52. PubMed ID: 19785057
[TBL] [Abstract][Full Text] [Related]
11. Cetuximab: potential role as first-line treatment for advanced non-small cell lung cancer.
Pirker R
Clin Adv Hematol Oncol; 2008 Oct; 6(10):735-6. PubMed ID: 18997663
[No Abstract] [Full Text] [Related]
12. Epidermal growth factor receptor inhibitors in the treatment of non-small cell lung cancer.
Agelaki S; Georgoulias V
Expert Opin Emerg Drugs; 2005 Nov; 10(4):855-74. PubMed ID: 16262567
[TBL] [Abstract][Full Text] [Related]
13. EGFR-directed therapies to treat non-small-cell lung cancer.
Ho C; Laskin J
Expert Opin Investig Drugs; 2009 Aug; 18(8):1133-45. PubMed ID: 19572809
[TBL] [Abstract][Full Text] [Related]
14. Cetuximab and other anti-epidermal growth factor receptor monoclonal antibodies in the treatment of non-small cell lung cancer.
Gridelli C; Maione P; Ferrara ML; Rossi A
Oncologist; 2009 Jun; 14(6):601-11. PubMed ID: 19482958
[TBL] [Abstract][Full Text] [Related]
15. The role of EGFR inhibition in the treatment of non-small cell lung cancer.
Ray M; Salgia R; Vokes EE
Oncologist; 2009 Nov; 14(11):1116-30. PubMed ID: 19892771
[TBL] [Abstract][Full Text] [Related]
16. Unanswered questions: monoclonal antibodies in the treatment of advanced non-small-cell lung cancer.
Gridelli C; Rossi A
Oncology (Williston Park); 2010 Nov; 24(13):1216-23. PubMed ID: 21192561
[TBL] [Abstract][Full Text] [Related]
17. Controversies around the use of monoclonal antibodies in the treatment of advanced non-small cell lung cancer.
Dediu M; Ion O; Ion R; Gal C; Median D; Gongu M
J BUON; 2009 Sep; 14 Suppl 1():S159-64. PubMed ID: 19785059
[TBL] [Abstract][Full Text] [Related]
18. Biological agents in non-small cell lung cancer: a review of recent advances and clinical results with a focus on epidermal growth factor receptor and vascular endothelial growth factor.
Kelly K; Huang C
J Thorac Oncol; 2008 Jun; 3(6):664-73. PubMed ID: 18520811
[TBL] [Abstract][Full Text] [Related]
19. Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer.
Thienelt CD; Bunn PA; Hanna N; Rosenberg A; Needle MN; Long ME; Gustafson DL; Kelly K
J Clin Oncol; 2005 Dec; 23(34):8786-93. PubMed ID: 16246975
[TBL] [Abstract][Full Text] [Related]
20. [Stage IV NSCLC. Biological treatments of lung cancer in 2008... and in the near future].
Bergot E; Levallet G; Zalcman G
Rev Mal Respir; 2008 Oct; 25(8 Pt 2):3S119-26. PubMed ID: 18971836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]